EGRX Key Statistics, Chart & Performance
The current stock price of EGRX is 2.14 USD. In the past month the price decreased by -53.58%. In the past year, price decreased by -84.56%.
EGRX Latest News, Press Relases and Analysis
EGRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About EGRX
Company Profile
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Company Info
EAGLE PHARMACEUTICALS INC
50 Tice Boulevard, Suite 315
Woodcliff Lake NEW JERSEY 07677 US
CEO: Scott Tarriff
Employees: 134
Phone: 12013265300
EAGLE PHARMACEUTICALS INC / EGRX FAQ
What does EGRX do?
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
What is the current price of EGRX stock?
The current stock price of EGRX is 2.14 USD. The price decreased by -39.89% in the last trading session.
Does EGRX stock pay dividends?
EGRX does not pay a dividend.
What is the ChartMill rating of EAGLE PHARMACEUTICALS INC stock?
EGRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for EAGLE PHARMACEUTICALS INC?
EAGLE PHARMACEUTICALS INC (EGRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for EAGLE PHARMACEUTICALS INC?
EAGLE PHARMACEUTICALS INC (EGRX) will report earnings on 2024-11-04, after the market close.
What is the outstanding short interest for EAGLE PHARMACEUTICALS INC?
The outstanding short interest for EAGLE PHARMACEUTICALS INC (EGRX) is 0.37% of its float.
EGRX Technical Analysis
EGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EGRX. While EGRX belongs to the best of the industry regarding profitability, there are concerns on its financial health.
EGRX Financial Highlights
Over the last trailing twelve months EGRX reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS decreased by -33.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.7% | ||
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| Debt/Equity | 0.25 |
EGRX Forecast & Estimates
7 analysts have analysed EGRX and the average price target is 17.34 USD. This implies a price increase of 710.28% is expected in the next year compared to the current price of 2.14.
For the next year, analysts expect an EPS growth of -40.26% and a revenue growth -19.31% for EGRX